David A. Giljohann
Chief Executive Officer
Dr. Giljohann has served as our CEO since November 2013 and been on our board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was our Chief Operating Officer. From 2011 until June 2012, Dr. Giljohann served as our principal scientist. Dr. Giljohann was our founding scientist in 2011. Prior to that, Dr. Giljohann was the founding scientist of AuraSense, LLC, our largest stockholder, in 2009. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and Spherical Nucleic Acid (SNA™) constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist's "Top 40 Under 40 Power List" in 2014. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.
David Snyder
Chief Financial Officer
Mr. Snyder joined our executive leadership team as Chief Financial Officer in July 2014. Prior to joining the Company, Mr. Snyder was Executive Vice President and Chief Financial Officer of Cellular Dynamics International, Inc. where he was responsible for all financial functions, human resources, and general administration. Mr. Snyder previously served as Senior Vice President of Finance, Site Vice President and Chief Financial Officer of Roche NimbleGen from 2007 to 2008. From 2006 to 2007, he served as Vice President and Chief Financial Officer of NimbleGen Systems, Inc. At NimbleGen, Mr. Snyder helped prepare the company for an IPO and then helped manage the sale of NimbleGen to Roche. Prior to NimbleGen, Mr. Snyder was the Chief Financial Officer of a variety of public and private companies within software, real estate, and diversified manufacturing industries. He has served as a director of Invenra, Inc. since 2012. He also served on the Board of Trustees of Ottawa University from 2012 to 2014. Mr. Snyder received a B.A., summa cum laude, from Ottawa University and an M.B.A. with high honors from the Harvard Business School, where he was designated a George Fisher Baker Scholar.
Ekambar Kandimalla
Chief Scientific Officer
Dr. Kandimalla has served as our Chief Scientific Officer since October 2015, bringing over 20 years of discovery research and preclinical drug development experience. Dr. Kandimalla has led discovery of oligonucleotide therapeutics targeting mRNA, miRNA and Toll-like receptors for the treatment of broad disease indications, including cancers, asthma-allergies, autoimmune, cardiovascular and metabolic diseases. Dr. Kandimalla has extensive experience in oligonucleotide chemistry, in vitro and in vivo pharmacology, target identification and validation to late stage discovery. From June 2014 to October 2015, Dr. Kandimalla served as Chief Scientific Officer of ChemGenes Corporation. Dr. Kandimalla was at Idera Pharmaceuticals Inc. (formerly Hybridon, Inc.) from June 1992 to June 2014, in various roles of increasing responsibility, including serving as Vice President of discovery, where he was responsible for generating new product pipeline, support early drug development, establish and maintain external scientific collaborations. Prior to joining Hybridon, Dr. Kandimalla has carried out postdoctoral research at Molecular Biophysics Unit of Indian Institute of Science, and Department of Chemistry of the University of Alberta. Dr. Kandimalla is an author on over 150 publications, including reviews and book chapters, and a co-inventor on about 300 issued/pending patents worldwide. Dr. Kandimalla has a Ph.D. in Chemistry, M.Sc. in Biochemistry and B.Sc. in Chemistry, all from Andhra University, India.
Jocelyn Trokenheim
Vice President, Head of Business Development
Ms. Trokenheim joined our executive leadership team in January 2018. Prior to joining Exicure, Ms. Trokenheim spent 15 years at Takeda Pharmaceuticals, most recently as Vice President of Corporate Development, where she was responsible for global strategic transactions, such as large-scale M&A, divestitures, and strategic partnering. Before that, she served as Head of Global Business Development Strategy and Operations, where she led the creation and implementation of Takeda’s business development strategy, as well as spearheading cross-functional collaborations to improve organizational efficiency and effectiveness globally. Ms. Trokenheim began her career as a consultant at ZS Associates, a global management consulting firm. Ms. Trokenheim received bachelor’s degree and an MSBA degree in Business Analysis from San Francisco State University, and an M.Sc. in Management Science from Queen’s University in Kingston, Ontario, Canada. Ms. Trokenheim was awarded as one of 15 Emerging Pharma Leaders by Pharmaceutical Executive magazine in August 2014.